サンプル依頼リスト カート
  • English
  • Korean
表紙：アルツハイマー治療の世界市場レポート2023年版
市場調査レポート
商品コード
1210197

アルツハイマー治療の世界市場レポート2023年版

Alzheimer's Disease Treatment Global Market Report 2023
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 250 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
アルツハイマー治療の世界市場レポート2023年版
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 250 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

世界のアルツハイマー治療市場は、2021年の47億1,000万米ドルから2022年には年平均成長率（CAGR）7.9％で50億8,000万米ドルに拡大すると予想されています。ロシア・ウクライナ戦争は、少なくとも短期的には、COVID-19の大流行からの世界経済回復の可能性を混乱させました。この2国間の戦争は、複数の国に対する経済制裁、商品価格の高騰、サプライチェーンの混乱につながり、商品やサービス全体にインフレを引き起こし、世界中の多くの市場に影響を与えています。アルツハイマー治療薬市場は、2026年にはCAGR8.1%で69億4000万米ドルに達すると予想されています。

2022年のアルツハイマー治療市場において、北米は最大の地域です。中東は予測期間中、最も急速に成長する地域と予想されます。アルツハイマー治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北アメリカ、南アメリカ、中東・アフリカです。

アルツハイマーの症例が増加していることは、アルツハイマー治療市場の成長に寄与する主要な要因です。アルツハイマー型認知症は、最も一般的な認知症の一種です。米国アルツハイマー協会では、老年人口の増加により、2025年までに米国の全州でアルツハイマー患者数が少なくとも14％増加すると予測しています。また、世界レベルでは、アルツハイマーの新規発症者数は、2030年には35％増の615,000人、2050年には110％増の959,000人になると推定されています。したがって、アルツハイマーの有病率の増加は、世界のアルツハイマー治療市場の成長を促進すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 アルツハイマー治療市場の特徴

第3章 アルツハイマー治療市場の動向と戦略

第4章 アルツハイマー治療市場- マクロ経済シナリオ

第4章 1 COVID-19がアルツハイマー治療市場に与える影響

第4章 2ウクライナとロシアの戦争がアルツハイマー治療市場に与える影響

第4章 3高インフレがアルツハイマー治療市場に与える影響

第5章 アルツハイマー治療の市場規模と成長

  • 世界のアルツハイマー治療市場の実績、2017-2022
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のアルツハイマー治療市場の予測、2022-2027F、2032F
    • 市場の促進要因
    • 市場の抑制要因

第6章 アルツハイマー治療市場セグメンテーション

  • 世界のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • コリン作動性
  • メマンチン
  • 配合剤
  • AChE阻害剤
  • 免疫グロブリン
  • 世界のアルツハイマー治療市場、薬剤タイプ別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • コリンエステラーゼ阻害剤
  • NMDA受容体拮抗薬
  • 世界のアルツハイマー治療市場、治療法別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F
  • コリンエステラーゼ阻害剤
  • NMDA受容体拮抗薬
  • その他の治療法

第7章 アルツハイマー治療市場の地域および国分析

  • 世界のアルツハイマー治療市場、地域別、実績と予測、2017-2022、2022-2027F、2032F
  • 世界のアルツハイマー治療市場、国別、実績と予測、2017-2022、2022-2027F、2032F

第8章 アジア太平洋アルツハイマー治療市場

  • アジア太平洋アルツハイマー治療市場概要
  • 地域情報, COVID-19の影響,市場情報,背景情報,政府のイニシアチブ,規制,規制機関,主要団体,課税される税,法人税構造,投資,主要企業
  • アジア太平洋アルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第9章 中国のアルツハイマー治療市場

  • 中国のアルツハイマー治療市場概要
  • 中国のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第10章 インドのアルツハイマー治療市場

  • インドのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第11章 日本のアルツハイマー治療市場

  • 日本のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第12章 オーストラリアのアルツハイマー治療市場

  • オーストラリアのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第13章 インドネシアのアルツハイマー治療市場

  • インドネシアのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第14章 韓国のアルツハイマー治療市場

  • 韓国のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第15章 西欧のアルツハイマー治療市場

  • 西欧のアルツハイマー治療市場概要
  • 西欧のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第16章 英国のアルツハイマー治療市場

  • 英国のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第17章 ドイツのアルツハイマー治療市場

  • ドイツのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第18章 フランスのアルツハイマー治療市場

  • フランスのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第19章 東欧のアルツハイマー治療市場

  • 東欧のアルツハイマー治療市場概要
  • 東欧のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第20章 ロシアのアルツハイマー治療市場

  • ロシアのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第21章 北米のアルツハイマー治療市場

  • 北米のアルツハイマー治療市場概要
  • 北米のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第22章 米国のアルツハイマー治療市場

  • 米国のアルツハイマー治療市場概要
  • 米国アルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第23章 南米のアルツハイマー治療市場

  • 南米のアルツハイマー治療市場概要
  • 南米のアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第24章 ブラジルのアルツハイマー治療市場

  • ブラジルのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第25章 中東アルツハイマー治療市場

  • 中東アルツハイマー治療市場概要
  • 中東アルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第26章 アフリカのアルツハイマー治療市場

  • アフリカのアルツハイマー治療市場概要
  • アフリカのアルツハイマー治療市場、薬剤クラス別セグメンテーション、実績と予測、2017-2022、2022-2027F、2032F

第27章 アルツハイマー治療市場の競合情勢と企業プロファイル

  • アルツハイマー治療市場の競合情勢
  • アルツハイマー治療市場の企業プロファイル
    • Allergan
    • Eisai Co. Ltd.
    • Novartis AG
    • Pfizer Inc.
    • Merz Pharma

第28章 アルツハイマー治療のパイプライン分析

第29章 アルツハイマー治療市場における主要な合併と買収

第30章 アルツハイマー治療市場の将来展望と潜在的分析

第31章 付録

目次
Product Code: r2050

“Alzheimer's Disease Treatment Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on alzheimer's disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for alzheimer's disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The alzheimer's disease treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Drug Class: Cholinergic; Memantine; Combined Drug; AChE inhibitors; Immunoglobulins

2) By Drug Type: Cholinesterase Inhibitors; NMDA Receptor Antagonists

3) By Therapeutics: Cholinesterase Inhibitors; NMDA Receptor Antagonists; Other Therapeutics

Companies Mentioned: Allergan; Eisai Co. Ltd.; Novartis AG; Pfizer Inc.; Merz Pharma

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the alzheimer's disease treatment market are: Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.

The global Alzheimer's disease treatment market is expected to grow from $4.71 billion in 2021 to $5.08 billion in 2022 at a compound annual growth rate (CAGR) of 7.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The Alzheimer's disease treatment market is expected to reach $6.94 billion in 2026 at a CAGR of 8.1%.

The Alzheimer's disease treatment market includes revenues earned by entities by temporarily improve symptoms of memory loss and problems with thinking and reasoning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

Alzheimer's diseas treatment refers to a medication designed and developed to treat Alzheimer's. This treatment, which targets the protein beta-amyloid and is an immunotherapy, aids in the reduction of amyloid plaques, which are brain lesions connected to Alzheimer's disease. The progression of this disease causes severe memory impairment and the person may lose the ability to carry out everyday tasks.

North America is the largest region in the alzheimer's disease treatment market in 2022. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the alzheimer's disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main types of drugs in alzheimer's disease treatment are cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors (also known as acetylcholinesterase inhibitors) are a class of drugs that prevent acetylcholine from being broken down normally. The different drug classes include cholinergic, memantine, combined drug, AChE inhibitors, and immunoglobulins and involve various therapeutics such as cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics.

The increasing cases of Alzheimer's are a major factor contributing to the growth of the Alzheimer's treatment market. Alzheimer's is the most common type of dementia. The USA Alzheimer's Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer's people by 2025 due to the increase in the geriatric population. At the global level, the estimated new cases of Alzheimer's are expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050. Therefore, the increasing prevalence of Alzheimer's disease is expected to drive the growth of the global Alzheimer's disease treatment market.

The lack of techniques for diagnosing Alzheimer's disease (AD) is expected to limit the growth of the global Alzheimer's disease treatment market. There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the primary clinical symptom of AD, making the diagnosis complicated. The lack of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists use a variety of approaches for diagnosis to confirm dementia, but it is still difficult to find the cause resulting in late diagnosis. Lack of proper and quick diagnosis for AD hampers the market growth as it leads to a reduced number of diagnosed cases and thereby reduces the consumption of AD drugs.

Increasing R&D investments and collaborations due to the emerging technologies for the treatment is a key trend in Alzheimer's disease (AD) treatment market. The Alzheimer's Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer's studies. Technologies such as B-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field on their peptidomimetic series. Manufacturing companies such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, and vTv Therapeutics are more focused on R&D investments with their research molecules in the clinical trials to achieve a breakthrough for the treatment of AD.

In January 2020, Biogen Inc., a US-based multinational biotechnology company acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer's disease (AD) and Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Parkinson's disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development, and manufacture of healthcare products including medicines and vaccines.

The countries covered in the alzheimer's disease treatment market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The alzheimer's disease treatment market research report is one of a series of new reports from The Business Research Company that provides alzheimer's disease treatment market statistics, including alzheimer's disease treatment industry global market size, regional shares, competitors with an alzheimer's disease treatment market share, detailed Alzheimer's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Alzheimer's disease treatment industry. This Alzheimer's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Table of Contents

1. Executive Summary

2. Alzheimer's Disease Treatment Market Characteristics

3. Alzheimer's Disease Treatment Market Trends And Strategies

4. Alzheimer's Disease Treatment Market - Macro Economic Scenario

4.1 COVID-19 Impact On Alzheimer's Disease Treatment Market

4.2 Ukraine-Russia War Impact On Alzheimer's Disease Treatment Market

4.3 Impact Of High Inflation On Alzheimer's Disease Treatment Market

5. Alzheimer's Disease Treatment Market Size And Growth

  • 5.1. Global Alzheimer's Disease Treatment Historic Market, 2017-2022, $ Billion
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints On The Market
  • 5.2. Global Alzheimer's Disease Treatment Forecast Market, 2022-2027F, 2032F, $ Billion
    • 5.2.1. Drivers Of The Market
    • 5.2.2. Restraints On the Market

6. Alzheimer's Disease Treatment Market Segmentation

  • 6.1. Global Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Cholinergic
  • Memantine
  • Combined Drug
  • AChE inhibitors
  • Immunoglobulins
  • 6.2. Global Alzheimer's Disease Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • 6.3. Global Alzheimer's Disease Treatment Market, Segmentation By Therapeutics, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonists
  • Other Therapeutics

7. Alzheimer's Disease Treatment Market Regional And Country Analysis

  • 7.1. Global Alzheimer's Disease Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • 7.2. Global Alzheimer's Disease Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific Alzheimer's Disease Treatment Market

  • 8.1. Asia-Pacific Alzheimer's Disease Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China Alzheimer's Disease Treatment Market

  • 9.1. China Alzheimer's Disease Treatment Market Overview
  • 9.2. China Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India Alzheimer's Disease Treatment Market

  • 10.1. India Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan Alzheimer's Disease Treatment Market

  • 11.1. Japan Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia Alzheimer's Disease Treatment Market

  • 12.1. Australia Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia Alzheimer's Disease Treatment Market

  • 13.1. Indonesia Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea Alzheimer's Disease Treatment Market

  • 14.1. South Korea Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe Alzheimer's Disease Treatment Market

  • 15.1. Western Europe Alzheimer's Disease Treatment Market Overview
  • 15.2. Western Europe Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK Alzheimer's Disease Treatment Market

  • 16.1. UK Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany Alzheimer's Disease Treatment Market

  • 17.1. Germany Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France Alzheimer's Disease Treatment Market

  • 18.1. France Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe Alzheimer's Disease Treatment Market

  • 19.1. Eastern Europe Alzheimer's Disease Treatment Market Overview
  • 19.2. Eastern Europe Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia Alzheimer's Disease Treatment Market

  • 20.1. Russia Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America Alzheimer's Disease Treatment Market

  • 21.1. North America Alzheimer's Disease Treatment Market Overview
  • 21.2. North America Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA Alzheimer's Disease Treatment Market

  • 22.1. USA Alzheimer's Disease Treatment Market Overview
  • 22.2. USA Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America Alzheimer's Disease Treatment Market

  • 23.1. South America Alzheimer's Disease Treatment Market Overview
  • 23.2. South America Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil Alzheimer's Disease Treatment Market

  • 24.1. Brazil Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East Alzheimer's Disease Treatment Market

  • 25.1. Middle East Alzheimer's Disease Treatment Market Overview
  • 25.2. Middle East Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa Alzheimer's Disease Treatment Market

  • 26.1. Africa Alzheimer's Disease Treatment Market Overview
  • 26.2. Africa Alzheimer's Disease Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. Alzheimer's Disease Treatment Market Competitive Landscape And Company Profiles

  • 27.1. Alzheimer's Disease Treatment Market Competitive Landscape
  • 27.2. Alzheimer's Disease Treatment Market Company Profiles
    • 27.2.1. Allergan
      • 27.2.1.1. Overview
      • 27.2.1.2. Products and Services
      • 27.2.1.3. Strategy
      • 27.2.1.4. Financial Performance
    • 27.2.2. Eisai Co. Ltd.
      • 27.2.2.1. Overview
      • 27.2.2.2. Products and Services
      • 27.2.2.3. Strategy
      • 27.2.2.4. Financial Performance
    • 27.2.3. Novartis AG
      • 27.2.3.1. Overview
      • 27.2.3.2. Products and Services
      • 27.2.3.3. Strategy
      • 27.2.3.4. Financial Performance
    • 27.2.4. Pfizer Inc.
      • 27.2.4.1. Overview
      • 27.2.4.2. Products and Services
      • 27.2.4.3. Strategy
      • 27.2.4.4. Financial Performance
    • 27.2.5. Merz Pharma
      • 27.2.5.1. Overview
      • 27.2.5.2. Products and Services
      • 27.2.5.3. Strategy
      • 27.2.5.4. Financial Performance

28. Alzheimer's Disease Treatment Pipeline Analysis

29. Key Mergers And Acquisitions In The Alzheimer's Disease Treatment Market

30. Alzheimer's Disease Treatment Market Future Outlook and Potential Analysis

31. Appendix

  • 31.1. Abbreviations
  • 31.2. Currencies
  • 31.3. Historic And Forecast Inflation Rates
  • 31.4. Research Inquiries
  • 31.5. The Business Research Company
  • 31.6. Copyright And Disclaimer